Navigation Links
Amgen and Peregrine Under StockCall Scrutiny: Pharma Stocks Deal with Drug Developments and Patents
Date:2/6/2013

of its revenue from Neupogen franchise. However, the drug would go off patent protection by the end of 2013 and the loss of exclusivity is expected to affect Amgen. Neupogen faces stiff competition from the companies like Novartis in the markets outside of the U.S. and these competing companies may launch their products in the U.S., causing further damage. However, the company has somewhat strong drug candidates including AMG145, a cholesterol drug candidate.

Amgen stock grew over 25 percent in the past 12 months. It also offers good dividend yield of 2.17 percent. The company is likely to increase its dividend in the future, thus offering good returns to the investors. Amgen is also growing through acquisitions as it recently completed the purchase of Icelandic company decode Genetics.

Peregrine Struggles with Cancer Drug Development

Peregrine Pharmaceuticals Inc. specializes in developing therapies for viral infections. It also develops treatments for cancers. It is currently engaged in developing treatment for non-small cell lung cancer. If successful, the company will make big fortunes as non-small cell lung cancer accounts for about 80 percent of lung cancer cases. However, the company does not have very solid track record. The drug candidate bavituximab has been controversial as it led to the stock's massive tumble in September 2012. Sign up to download the free technical analysis on Peregrine Pharmaceuticals at

http://www.StockCall.com/PPHM020613.pdf  

Peregrine is a small company with the market capitalization of less than $300 million. The stock is quite volatile as well. The company is currently looking to get past the phase II for bavituximab. Overall, the stock may be held if it is already in your portfolio. On the upside, the stock is currently trading about 50 percent below its 52-week high, thus in case of positive news on its
'/>"/>

SOURCE StockCall.com
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Amgen to Acquire Mustafa Nevzat, a Leading Privately Held Turkish Pharmaceutical Company
2. Four Californians Selected As Breakaway from Cancer® Champions To Be Honored During Amgen Tour of California
3. Amgen to Present at the Baird Growth Stock Conference
4. Amgen To Provide Testimony At FDA Stakeholder Hearing On Biosimilars
5. Amgens BiTE® Antibody Blinatumomab (AMG 103) Achieved High Rate of Complete Response in Adult Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia
6. Amgen Announces Top-Line Results Of Phase 3 Sensipar®/Mimpara® EVOLVE™ Trial
7. Amgen Completes Acquisition of Mustafa Nevzat Pharmaceuticals
8. Amgen Completes Acquisition of KAI Pharmaceuticals
9. Amgens Second Quarter 2012 Revenues Increased 13 Percent To $4.5 Billion And Adjusted Earnings Per Share (EPS) Increased 34 Percent To $1.83
10. Amgen Announces Termination Of Ganitumab Phase 3 Study For Futility In Metastatic Pancreatic Cancer
11. Amgen To Present At The Baird Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/29/2014)... , Aug. 29, 2014   Mast Therapeutics, ... company, announced today that Santosh Vetticaden, Chief Medical ... the Company, for personal reasons, in mid-September.  ... Officer of Aires Pharmaceuticals, which Mast acquired earlier ... as the Company,s interim Chief Medical Officer.  Dr. ...
(Date:8/29/2014)... 29, 2014 Research and Markets ... Instrument Industry Report, 2014-2017" report to their offering. ... rising proportion of reimbursement for medical expenses, the Chinese ... its scale presenting a CAGR of 19.2% during 2009-2013. ... product segments of orthopedic instruments in China ...
(Date:8/29/2014)... -- Does your doctor know what you,re smoking?  Chances are, ... to the over 112,000 currently registered patients under ... other roughly 20,300+ active physicians listed with the Colorado Dept ... even though a poll in February 2014 showed 51% of ... it. "With marijuana legalization underway, every doctor ...
Breaking Medicine Technology:Mast Therapeutics Announces Management Change 2Mast Therapeutics Announces Management Change 3Mast Therapeutics Announces Management Change 4China Orthopedic Instrument Industry Report, 2014-2017 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 2Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 3Medical Rules Marijuana Sales in Colorado But Most Doctors Still in the Dark 4
... 16, 2007 - Somanta,Pharmaceuticals (OTCBB:SMPM) today announced ... presented later today at the American,Association for ... The poster presentation is entitled "Cytotoxicity of ... Excision,Repair and DNA Mismatch Repair defects," and ...
... Second Half of 2007 -, BRISBANE, Australia, April ... the final stage 1,results of its Phase 2 ... surgical removal of liver cancer. The 48 week,data ... improvement in,disease-free rate, the primary endpoint, of 25 ...
Cached Medicine Technology:Somanta Announces the Presentation of Alchemix Data at The American,Association for Cancer Research Annual Meeting 2Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective 2Progen's Phase 2 Liver Cancer Trial Exceeds Efficacy Objective 3
(Date:9/1/2014)... News) -- Watching action shows on TV may be bad ... much more snack food while watching action films and programs ... "We find that if you,re watching an action movie ... author Aner Tal, of the Cornell Food and Brand Lab, ... more distracting the program is, the more you will eat." ...
(Date:9/1/2014)... Currently, scientists continue to face fundamental ... disease (AD), which reflects their poor understanding of ... of the disease, especially in its early stages, ... In 2014, after decades that have witnessed ... medicine world, there are still no disease-modifying therapies ...
(Date:9/1/2014)... New York, NY (PRWEB) September 01, 2014 ... filings have been added to a federal litigation that ... of South Carolina, Bernstein Liebhard LLP reports. , ... 1,162 claims now filed over the widely-used cholesterol medication ... to the drug. According to claims, Pfizer Inc. failed ...
(Date:9/1/2014)... The B-cell non-Hodgkin’s Lymphoma (NHL) treatment market value ... US, France, Italy, Germany, Spain and the UK), from ... , The competitive landscape in the B-cell NHL markets ... UK is poised to undergo a dramatic shift during ... B-cell NHL indications, which includes Diffuse Large B-Cell Lymphoma ...
(Date:9/1/2014)... Monday 1 September 2014: Daily fruit consumption cuts ... 40%, according to research presented at ESC Congress today ... from the seven year follow-up study of nearly 0.5 ... the more fruit people ate, the more their risk ... ischaemic heart disease (IHD) and stroke, is the leading ...
Breaking Medicine News(10 mins):Health News:Action-Packed TV a Threat to Your Waistline? 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 2Health News:Early Stage Minimally Invasive Candidate AD Biomarkers Reviewed in New Study by Biopharm Reports Available at MarketPublishers.com 3Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 2Health News:South Carolina Litigation Adds 200 Lipitor Lawsuits in a Month, as Plaintiffs File Suits Alleging New-Onset Diabetes, Bernstein Liebhard LLP Reports 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 2Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 3Health News:B-cell Non-Hodgkin Lymphoma Treatment Market Value worth $5.4 Billion by 2018 Says a New Report Available at MarketOptimizer.org 4Health News:Fruit consumption cuts CVD risk by up to 40 percent 2Health News:Fruit consumption cuts CVD risk by up to 40 percent 3
... Get Discount to Switch , ... ... provider of Internet practice management and www.CollaborateMD.com [medical ... program for existing users of Medisoft, Lytec, AltaPoint, Medical Manager ...
... supporters join call for fair & enforceable union,election ground ... is being issued by SEIU United Healthcare Workers - ... System and their supporters,presented an open letter to the ... women religious to help stop the unlawful threats and,intimidation ...
... Minn., Aug. 13 The CHS Foundation,announced today ... the Ralph K.,Morris Foundation,s new Elroy Webster Cooperative ... honorary award to graduate and law,students interested in ... created in memory of Elroy Webster, a,Minnesota farmer ...
... STEN ), a Minneapolis-based diversified business, today reported,results ... June 29,2008. The Company reported a net after-tax ... the third quarter period ended June 29, 2008. ... were $5,035,913, an,increase of 377 percent, or $3,979,309 ...
... cancer,research/programs, DETROIT, Aug. 13 Sean Shearon wanted ... cancer, as well as honor the victims,and survivors of ... 18,marathons in 18 days -- The Victory Walk -- ... programs at the Barbara Ann Karmanos Cancer,Institute, in Detroit. ...
... (August 13, 2008) SAGE, the world,s fifth largest journals ... agreement to publish the Journal of Dental Research ... publication of the International and American Associations for Dental Research ... dedicated to the dissemination of new knowledge and information on ...
Cached Medicine News:Health News:CollaborateMD Offers Upgrade Program to Competitors' Users 2Health News:As Charges Mount, Caregivers and Supporters Call on Sisters of St. Joseph of Orange to Help Stop Unlawful Intimidation of Workers 2Health News:CHS Foundation Helps Launch New Scholarship Fund 2Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 2Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 3Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 4Health News:STEN Corporation Reports 2008 Third-Quarter Revenue of $5 Million and Improved Results From Operations 5Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 2Health News:More Than 400-mile Victory Walk to Conclude Aug. 14, at Campus Martius 3Health News:SAGE to publish Journal of Dental Research beginning in 2009 2
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
Medicine Products: